Sangamo Therapeutics Inc (SGMO)
OTCHealth CareBiotechnologySnapshot 2026-09-04
$0.07+4.22%
Close 2026-07-28 · 1-day change
OTCHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Revenue stabilizes near $110M in 2026: FY26 guidance low $100M vs target ~$110M.
Sangamo is cutting costs to $100M-$120M in 2026. It is restructuring operations and cutting about 40% of its workforce. The company continues to operate under Chapter 11 bankruptcy protection. These steps may stabilize the business and reduce losses.
The company is loss-making and recently filed for bankruptcy. Revenue is volatile and expected to decline about 60%. The restructuring and cost cuts may not be enough to restore financial health.
The market prices in about a 60% revenue decline and a stretched 3-year growth contraction. Our fair value of $0.24 reflects this weak outlook. We see limited upside given ongoing bankruptcy and operational risks.
Breaks if: Company fails to maintain debtor-in-possession status or exits bankruptcy unfavorably
Continue operations as debtor-in-possession under Chapter 11 bankruptcy protection while restructuring.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. SGMO is navigating a volatile landscape with significant operational restructuring and regulatory ambitions, but its recent financial performance has been weak.
The market currently prices SGMO as a company facing challenges, reflected in its cheap valuation compared to peers. However, the expectations gap indicates that the market is not fully accounting for potential positive developments in the healthcare sector.
Management is focused on reducing operating expenses and advancing regulatory progress for its gene therapy product. However, the recent legal and regulatory events pose a high risk to its operational stability and financial recovery.
The future of SGMO depends on its ability to execute on cost-cutting measures, the success of its gene therapy regulatory submissions, and the overall momentum in the healthcare sector driven by larger players. Any cuts to guidance or worsening economic indicators could negatively impact sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q2. Management filed for Chapter 11 bankruptcy protection and continues operations as debtor-in-possession. Financials show net losses continuing with operating income negative $31.9M in 2026-Q1. This priority reflects the current legal and operational status amid financial challenges.
“Filed voluntary petition for relief under Chapter 11 and continue to operate as debtor-in-possession.”
Breaks if: Non-GAAP total operating expenses exceed $120 million in FY26
Continue to manage and reduce non-GAAP total operating expenses within $100 million to $120 million range for fiscal year 2026.
Stated as a priority in 3 of last 3 quarters. Management narrowed non-GAAP operating expenses guidance from $125M-$145M in 2025 to $100M-$120M in 2026. Non-GAAP operating expenses were $31.7M in 2026-Q1, consistent with the annual target range. The trajectory shows management delivering on cost discipline with reduced expense guidance and current quarter expenses aligned.
“We expect non-GAAP total operating expenses... in the range of approximately $100 million to $120 million in 2026.”
“We expect non-GAAP total operating expenses... in the range of approximately $110 million to $120 million in 2026.”
“We continue to expect non-GAAP total operating expenses... in the range of approximately $125 million to $145 million in 2025.”
Breaks if: Revenue falls below $100 million in FY26
Breaks if: Workforce reduction is less than 40% by 2026-Q2
Implement operational restructuring including workforce reduction of about 40% to reduce costs and align resources.
Newly stated in 2026-Q2. Management announced a workforce reduction of approximately 40%, eliminating 51 roles as part of operational restructuring. This is a recent development with no prior quarters stating this priority. The financials show reduced general and administrative expenses in 2026-Q1, consistent with early cost savings from restructuring.
“Board approved restructuring and workforce reduction of approximately 40%.”
In the next 1 to 3 years, SGMO's outlook will be shaped by its operational changes and sector dynamics. Not investment advice.